Frontiers in Oncology最新文献

{"title":"Mechanisms and molecular characterization of relapsed/refractory neuroblastomas.","authors":"Chong Chen, Zixuan Wei","doi":"10.3389/fonc.2025.1555419","DOIUrl":"https://doi.org/10.3389/fonc.2025.1555419","url":null,"abstract":"<p><p>Relapsed/refractory neuroblastoma is a type of malignant solid tumor with a very poor prognosis in children. Its pathogenesis is complex, involving multiple molecular pathways and genetic alterations. Recent studies have shown that MYCN amplification, ALK mutation, TERT promoter mutation, p53 pathway inactivation, and chromosomal instability are the key mechanisms and molecular characteristics of relapsed/refractory neuroblastoma. Precision treatment strategies targeting these molecular mechanisms have shown certain prospects in preclinical studies and clinical practice. This review focuses on the relevant mechanisms and molecular characteristics of relapsed/refractory neuroblastoma, explores its relationship with treatment response and clinical prognosis, and briefly introduces the current treatment strategies to provide a theoretical basis for the development of novel and personalized therapeutic regimens to improve the prognosis of children.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1555419"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of a multifunctional chemotherapy infusion device for reducing antineoplastic drug extravasation.","authors":"Li-Hua Yang, Li-Ping Liu, Fa-Ying Jiang, Feng-Zhu Huang, Chun-Fen Xie, Xue-Qin Lin, Pan Wang, Xiu-Li Feng","doi":"10.3389/fonc.2025.1539389","DOIUrl":"https://doi.org/10.3389/fonc.2025.1539389","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to address the challenges associated with antineoplastic drug extravasation during intravenous administration, through the development of a novel chemotherapy infusion device. A secondary objective was to mitigate associated risks to healthcare personnel, patients, caregivers and the environment.</p><p><strong>Methods: </strong>A water-soluble fluorescent solution was used as a surrogate for antineoplastic chemotherapy agents to assess the potential for drug extravasation and the associated risks of occupational exposure during intravenous administration. The investigation identified risks related to drug extravasation, which informed the development of the novel infusion device.</p><p><strong>Results: </strong>In experiment 1, conventional methods for replacing infusion bags resulted in drug extravasation during the second bag change across all procedures conducted by 9 operators. Specifically, extravasation was observed in 81 out of 90 procedures. In experiment 2, the newly designed multifunctional chemotherapy infusion device, which requires each infusion bag to be punctured only once, was used. Under these conditions, the same 9 operators performed 90 procedures, with extravasation occurring in only 2 instances.</p><p><strong>Conclusion: </strong>The multifunctional chemotherapy infusion device facilitates the efficient administration of intravenous chemotherapy while addressing the issue of drug extravasation associated with traditional infusion devices during the delivery of antineoplastic drugs. This device effectively reduces the risk of occupational injuries among healthcare workers, reduces harm to patients and their caregivers, and mitigates environmental contamination.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1539389"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11923124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Primary solid pseudopapillary neoplasm of the ovary with \"cholesteroma-like\" denaturation.","authors":"Ziqing Zhao, Jiahui Lin, Tingting Bai, Hongfeng Liao, Zhengjin Liu","doi":"10.3389/fonc.2025.1514460","DOIUrl":"https://doi.org/10.3389/fonc.2025.1514460","url":null,"abstract":"<p><p>Solid pseudopapillary neoplasms (SPNs) primarily arise in the pancreas and are uncommon in the ovaries. Here, we present a case of ovarian-origin SPN. Alongside the typical solid and pseudopapillary structures, \"cholesteroma-like\" denaturation areas and tissue degeneration regions are also observed. Immunohistochemistry analysis demonstrates positive results for β-catenin (nucleus), CD99 (dot-like), CD56, and vimentin. Imaging studies rule out pancreatic or other origins. This study aims to enhance comprehension, diagnosis, and differential diagnosis of primary ovarian SPN among pathologists and clinicians, as well as to investigate the origin and management of primary solid pseudopapillary tumors in the ovary.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1514460"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of an innovative multi-cancer early detection test: high sensitivity and specificity in differentiating cancer, inflammatory conditions, and healthy individuals.","authors":"Nike Walter, Jörg Groth, Berthold von Und Zu Zwerger","doi":"10.3389/fonc.2025.1520869","DOIUrl":"https://doi.org/10.3389/fonc.2025.1520869","url":null,"abstract":"<p><strong>Background: </strong>Cancer is a leading cause of death worldwide, with early detection crucial for effective treatment. Traditional diagnostic methods, such as imaging and biopsies, are often limited by invasiveness, cost, and sensitivity. Blood-based multi-cancer early detection (MCED) tests offer a less invasive and potentially more comprehensive approach. Recently, a novel screening tool, the Carcimun^® test was reported, detecting conformational changes in plasma proteins through optical extinction measurements. This study evaluates the Carcimun^® test's performance, including participants with inflammatory conditions.</p><p><strong>Methods: </strong>This prospective, single-blinded study included 172 participants: 80 healthy volunteers, 64 cancer patients (various types), and 28 individuals with inflammatory conditions (fibrosis, sarcoidosis, pneumonia) or benign tumors. Plasma samples were analyzed using the Carcimun^® test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated.</p><p><strong>Results: </strong>Mean extinction values were significantly higher in cancer patients (315.1) compared to healthy individuals (23.9) and those with inflammatory conditions (62.7) (p<0.001). The Carcimun^® test distinguished these groups with high accuracy (95.4%), sensitivity (90.6%), and specificity (98.2%). Significant differences were found between healthy participants and cancer patients (p<0.001), and between cancer patients and those with inflammation (p<0.001).</p><p><strong>Conclusion: </strong>The Carcimun^® test achieved high accuracy, sensitivity, and specificity, effectively identifying cancer patients while minimizing false positives and negatives. By including participants with inflammatory conditions, we addressed a significant limitation of previous studies, demonstrating the test's robustness in real-world clinical scenarios. These findings underscore the potential of the Carcimun^® test as a valuable tool for early cancer detection and screening.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1520869"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Global approaches to molecular diagnostics for pediatric cancer.","authors":"Jeremy R Wang, Thomas B Alexander","doi":"10.3389/fonc.2025.1578509","DOIUrl":"https://doi.org/10.3389/fonc.2025.1578509","url":null,"abstract":"","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1578509"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tislelizumab-induced type 1 diabetic ketoacidosis in a patient with small cell lung cancer: a case report.","authors":"Jie Zhu, Wen-Jie Wang","doi":"10.3389/fonc.2025.1498701","DOIUrl":"https://doi.org/10.3389/fonc.2025.1498701","url":null,"abstract":"<p><p>This report presented a case of 71-year-old man diagnosed with extensive-stage small cell lung cancer (ES-SCLC) who developed type 1 diabetic ketoacidosis (DKA) after 3 cycles of tislelizumab plus chemotherapy for the first time. The patient had no history of diabetes mellitus (DM). According to medical history and laboratory examination, the case was definitely diagnosed new-onset type 1 diabetic ketoacidosis induced by tislelizumab, a kind of immune checkpoint inhibitor. Despite the incidence of immune checkpoint inhibitor-induced type 1 diabetes mellitus (ICI-T1DM) is rare, the development of ICI-T1DM, especially type 1 diabetic ketoacidosis is life-threating without blood glucose monitoring and insulin therapy. Early identification of hyperglycemia and C-peptide depletion, as well as routine blood glucose monitoring during ICI treatment is essential to avoid lethal endocrine immune-related adverse event (irAE).</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1498701"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative versus adjuvant chemotherapy for resectable gastric cancer: a meta-analysis of randomized controlled trials.","authors":"Haiya Ou, Jiamei Zhuang, Mingwei Jian, Xinyi Zheng, Tingping Wu, Honghui Cheng, Rui Qian","doi":"10.3389/fonc.2025.1432596","DOIUrl":"https://doi.org/10.3389/fonc.2025.1432596","url":null,"abstract":"<p><strong>Objectives: </strong>To report the latest systematic review and meta-analysis of randomized controlled trials (RCT) to compare perioperative versus adjuvant chemotherapy for resectable gastric cancer.</p><p><strong>Methods: </strong>We conducted a systematic literature retrieval via PubMed, Embase, Web of Science, and Cochrane until April, 2024 for RCT which compared perioperative versus adjuvant chemotherapy for resectable gastric cancer. Outcomes measured were overall survival (OS) and progression-free survival (PFS).</p><p><strong>Results: </strong>5 RCTs including 2,735 patients were included for meta-analysis. Meta-analysis revealed a significant longer PFS in the neoadjuvant chemotherapy (NAC) group (HR: 0.77; 95% CI: 0.69, 0.85; <i>P</i><0.00001) compared with adjuvant chemotherapy (AC) group. Subgroup analysis found that there was still a significant superiority of NAC in female (HR: 0.53; 95% CI: 0.40, 0.70; <i>P</i><0.0001) and cN+ (HR: 0.77; 95% CI: 0.67, 0.89; <i>P</i>=0.0005) patients, while the superiority disappeared in male (HR: 0.87; 95% CI: 0.74, 1.01; <i>P</i>=0.07) and cN- patients (HR: 0.91; 95% CI: 0.46, 1.78; <i>P</i>=0.77). In addition, meta-analysis observed a trend towards improved OS with NAC (HR: 0.86; 95% CI: 0.70, 1.07; <i>P</i> = 0.17), and sensitivity analysis demonstrated instability in OS.</p><p><strong>Conclusions: </strong>NAC can significantly prolong PFS in patients with resectable gastric cancer compared to AC, and the benefit is more significant in women and cN+ patients. Besides, our analysis indicated that NAC has a potential to improve OS compared with AC.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024546165.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1432596"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The top 100 papers on prostate cancer-associated exosomes on social media: an altmetric study from the MENA region.","authors":"Nasim Ansari, Faezeh Zaeri Basir, Mina Mahami-Oskouei, Roya Rashti, Ali Ouchi","doi":"10.3389/fonc.2025.1481406","DOIUrl":"https://doi.org/10.3389/fonc.2025.1481406","url":null,"abstract":"<p><strong>Purpose: </strong>This altmetric analysis aimed to identify and describe the top 100 papers on prostate cancer-associated exosomes in the Middle East and North Africa (MENA) region cited on social media.</p><p><strong>Design/methodology/approach: </strong>As an applied study with an altmetric approach, this research included all Science Citation Index (SCI) Expanded indexed papers on prostate cancer-associated exosomes in the MENA region during 1970-2023. Altmetric Attention Scores (AASs) were extracted from the Altmetric Explorer, and Excel and SPSS were used for data analysis.</p><p><strong>Finding: </strong>Twitter ranked first in mentioning 73.55 of the top 100 studied papers. The highest score of mentions on Twitter equaled 187, and that of AAS was 516, which belonged to an original research article. However, the top paper in citation counts was a guideline (AAS = 116; citation count = 5,664 =). The <i>Journal of Urology</i> published most papers (n = 21), with total AAS = 1,094. Most papers were international collaborations (n = 82). There was no significant relationship between the AASs of papers and those of Web of Science (WoS) citation counts (R² = 0.1284, p-value = 0.2054).</p><p><strong>Practical implications: </strong>Showing a broad perspective on the research priorities and new directions in prostate cancer-associated exosomes, this study can be a guideline for finding main papers on diagnosing, treating, and preventing prostate cancer. It helps researchers, professionals, and policymakers in developing the use of social media in disseminating related information.</p><p><strong>Originality: </strong>By providing helpful information on prostate cancer-associated exosomes, this study can inform researchers and administrators of the state of research on the topic and consequent health promotion among the public.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1481406"},"PeriodicalIF":3.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11922722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptional and microbial profile of gastric cancer patients infected with Epstein-Barr virus.","authors":"Klezzer de Oliveira Carneiro, Taíssa Maíra Thomaz Araújo, Ronald Matheus Da Silva Mourão, Samir Mansour Moraes Casseb, Samia Demachki, Fabiano Cordeiro Moreira, Ândrea Kely Campos Ribeiro Dos Santos, Geraldo Ishak, Daniel de Souza Avelar Da Costa, Leandro Magalhães, Amanda Ferreira Vidal, Rommel Mario Rodriguez Burbano, Paulo Pimentel de Assumpção","doi":"10.3389/fonc.2025.1530430","DOIUrl":"10.3389/fonc.2025.1530430","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer (GC), which has low survival rates and high mortality, is a major concern, particularly in Asia and South America, with over one million annual cases. Epstein-Barr virus (EBV) is recognized as a carcinogen that may trigger gastric carcinogenesis by infecting the stomach epithelium via reactivated B cells, with growing evidence linking it to GC. This study investigates the transcriptional and microbial profiles of EBV-infected versus EBV-non-infected GC patients.</p><p><strong>Methods: </strong>Using Illumina NextSeq, cDNA libraries were sequenced, and reads were aligned to the human genome and analyzed with DESeq2. Kegg and differential analyses revealed key genes and pathways. Gene sensitivity and specificity were assessed using ROC curves (p < 0.05, AUC > 0.8). Non-aligned reads were used for microbiome analysis with Kraken2 for bacterial identification. Microbial analysis included LDA score, Alpha and Beta diversity metrics, with significance set at p ≤ 0.05. Spearman's correlation between differentially expressed genes (DEGs) and bacteria were also examined.</p><p><strong>Results: </strong>The data revealed a gene expression pattern in EBV-positive gastric cancer, highlighting immune response, inflammation, and cell proliferation genes (e.g., <i>GBP4</i>, <i>ICAM1</i>, <i>IL32</i>, <i>TNFSF10</i>). ROC analysis identified genes with high specificity and sensitivity for discriminating EBV+ gastric cancer, including <i>GBP5</i>, <i>CMKLR1</i>, <i>GM2A</i> and <i>CXCL11</i> that play pivotal roles in immune response, inflammation, and cancer. Functional enrichment pointed to cytokine-cytokine receptor interactions, antigen processing, and Th17 immune response, emphasizing the role of the tumor microenvironment, shaped by inflammation and immunomodulation, in EBV-associated GC. Microbial analysis revealed changes in the gastric microbiota in EBV+ samples, with a significant reduction in bacterial taxa. The genera <i>Choristoneura</i> and <i>Bartonella</i> were more abundant in EBV+ GC, while more abundant bacteria in EBV- GC included <i>Citrobacter</i>, <i>Acidithiobacillus</i> and <i>Biochmannia</i>. Spearman's correlation showed a strong link between DE bacterial genera and DEGs involved in processes like cell differentiation, cytokine production, digestion, and cell death.</p><p><strong>Conclusion: </strong>These findings suggest a complex interaction between the host (EBV+ GC) and the microbiota, possibly influencing cancer progression, and offering potential therapeutic targets such as microbiota modulation or gene regulation. Comparing with EBV- samples further highlights the specific impact of EBV and the microbiota on gastric cancer pathogenesis.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1530430"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective.","authors":"Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, Camila Noronha Santos, Milena Reis Santos de Oliveira, Anna Beatriz Willemes Batalha, Gabriella Sayuri de Alencar, Edna Harumi Goto, Juliana Francielle Marques, Marcia Puato Vieira Pupim, Adriana Seber","doi":"10.3389/fonc.2025.1540158","DOIUrl":"10.3389/fonc.2025.1540158","url":null,"abstract":"<p><strong>Introduction: </strong>In resource-limited countries, access to advanced therapies like CAR T-cell therapy is often unattainable. Clinical trials face challenges, with pediatric populations frequently excluded or experiencing significant delays. This highlights the need for alternative strategies to address high relapse risks in pediatric acute leukemia post-stem cell transplant.</p><p><strong>Methods: </strong>This retrospective study included pediatric acute leukemia patients who underwent HSCT between 2014 and 2024. Post-HSCT maintenance therapy became standard practice in 2021, utilizing agents like venetoclax, decitabine, azacitidine, blinatumomab, DLI, and targeted therapies. Primary outcomes were overall survival (OS) and disease-free survival (DFS); secondary outcomes included relapse rate and treatment-related toxicities.</p><p><strong>Results: </strong>Among 94 patients (64 with ALL, 30 with AML), ALL patients receiving maintenance therapy had an OS of 78% versus 47% without maintenance (p=0.02); DFS was 64% with maintenance and 45% without (p=0.12). In AML patients, maintenance was associated with an OS of 88% compared to 27% without. Relapse rates decreased in maintenance-treated patients, especially among AML patients with pre-transplant MRD positivity. Treatments were generally well-tolerated, with manageable toxicities.</p><p><strong>Discussion: </strong>Post-HSCT maintenance therapy is feasible in resource-limited settings and may improve survival outcomes. Strategies like hypomethylating agents with venetoclax in T-ALL and post-HSCT blinatumomab in B-ALL show potential benefits. Challenges include drug access and standardizing protocols. Further trials are needed to validate these findings in low- and middle-income countries.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1540158"},"PeriodicalIF":3.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}